These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18219812)

  • 21. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.
    Goodin DS; Biermann LD; Bohlega S; Boiko A; Chofflon M; Gebeily S; Gouider R; Havrdova E; Jakab G; Karabudak R; Karussis D; Miller A; Pakdaman H; Selmaj K; Sharief M;
    Curr Med Res Opin; 2007 Nov; 23(11):2823-32. PubMed ID: 17908370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
    Noseworthy JH
    Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
    [No Abstract]   [Full Text] [Related]  

  • 25. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent developments in multiple sclerosis therapeutics.
    Spain RI; Cameron MH; Bourdette D
    BMC Med; 2009 Dec; 7():74. PubMed ID: 19968863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
    Klawiter EC; Cross AH; Naismith RT
    Neurology; 2009 Sep; 73(12):984-90. PubMed ID: 19770475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future role of interferon beta in the therapy of multiple sclerosis.
    Farrell RA; Giovannoni G
    J Interferon Cytokine Res; 2010 Oct; 30(10):715-26. PubMed ID: 20874249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 30. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
    Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biological treatment of multiple sclerosis].
    Sørensen PS; Sellebjerg F
    Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.
    Bagert B; Camplair P; Bourdette D
    CNS Drugs; 2002; 16(7):445-55. PubMed ID: 12056920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
    Gold R; Rieckmann P
    Nervenarzt; 2007 Sep; 78 Suppl 1():15-24; quiz 25. PubMed ID: 17668159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
    Pawate S; Wang L; Song Y; Sriram S
    J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland.
    Bailey B
    Ir J Med Sci; 2011 Jun; 180(2):337-41. PubMed ID: 21293948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.
    Berger JR
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction therapy for patients with multiple sclerosis: why? When? How?
    Edan G; Le Page E
    CNS Drugs; 2013 Jun; 27(6):403-9. PubMed ID: 23657788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.